logo

India Diabetes Care Drugs Market Size (2024 - 2029)

The market size for diabetes drugs in India is projected to experience growth over the forecast period, driven by increased awareness and advancements in treatment options. The expanding availability of various diabetes medications, including newer drug classes, has enabled healthcare providers to offer more personalized treatment plans, leading to better patient outcomes. The rising prevalence of diabetes has also prompted a focus on preventive measures and early intervention, contributing to the market's expansion. Despite challenges such as limited access to healthcare and affordable medications, the growing understanding of diabetes management is expected to enhance the quality of life for patients, reflecting positively on the market's development.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Diabetes Industry in India Market Size

Market Size of India Diabetes Care Drugs Industry

India Diabetes Care Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 1.7 Billion
Market Size (2029) USD 2.01 Billion
CAGR (2024 - 2029) 3.50 %

Major Players

India Diabetes Care Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

India Diabetes Care Drugs Market Analysis

The India Diabetes Care Drugs Market size is estimated at USD 1.7 billion in 2024, and is expected to reach USD 2.01 billion by 2029, growing at a CAGR of 3.5% during the forecast period (2024-2029).

According to the study conducted by the Indian Council of Medical Research, India Diabetes (ICMR INDIAB) and published in 2023, the incidence of diabetes stands at 101 million individuals. Diabetes risk factors include race, age, obesity, physical inactivity, a poor diet, behavioral behaviors, genetics, and family history. Controlling blood sugar, blood pressure, and lipid levels can help behavioral behaviors void or postpone the onset of diabetic complications. Diabetes prevention and management pose a significant challenge in India due to several issues and barriers, including a lack of a multisectoral approach, surveillance data, awareness of diabetes, its risk factors and complications, access to health care settings, access to affordable medicines, and so on. 

This increase in the use of diabetes medications in India can be attributed to several factors. Firstly, there has been a growing awareness about diabetes and its complications among the general population, leading to more people seeking medical help and treatment for the condition. Additionally, advancements in diabetes drug treatments have made it easier for healthcare providers to manage the disease effectively.

The availability of a wide range of diabetes medications, including oral medications, insulin injections, and newer classes of drugs such as SGLT-2 inhibitors and GLP-1 receptor agonists, has provided healthcare providers with more options to tailor treatment plans to individual patient needs. This has resulted in better glycemic control and improved outcomes for many diabetic patients.

Furthermore, the increasing prevalence of diabetes in India has also led to a greater emphasis on preventive measures and early intervention, prompting more people to seek medical advice and start treatment at an earlier stage of the disease. This proactive approach has helped to reduce the burden of diabetes-related complications and improve the overall quality of life for diabetic individuals in India.

Overall, the rise in the use of diabetes medications in India is a positive development that reflects the growing awareness and understanding of diabetes as a chronic disease that requires ongoing management and treatment. With continued advancements in diabetes drug treatments and increased access to healthcare services, the diabetic population in India can look forward to better outcomes and improved quality of life in the years to come.

India Diabetes Care Drugs Industry Segmentation

Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin the body's cells do not respond properly to insulin, or both. India's diabetes care drugs segment market into insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.

Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Need A Different Region Or Segment?
Customize Now

India Diabetes Care Drugs Market Size Summary

The India Diabetes Drugs Market is poised for growth, driven by increasing awareness and advancements in diabetes management. The market is characterized by a diverse range of medications, including oral drugs, insulin injections, and newer classes such as SGLT-2 inhibitors and GLP-1 receptor agonists. This variety allows healthcare providers to customize treatment plans, improving glycemic control and patient outcomes. The rising prevalence of diabetes, influenced by factors such as urbanization, lifestyle changes, and genetic predispositions, has led to a greater emphasis on early intervention and preventive measures. Despite challenges like limited access to healthcare and affordable medications, the market is expected to expand as more individuals seek treatment and as healthcare infrastructure improves.

The competitive landscape of the India Diabetes Drugs Market is moderately fragmented, with major players like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb dominating the insulin and SGLT-2 drug segments. The oral drug market sees significant participation from generic manufacturers. The intensity of competition is high, with companies striving to innovate and offer competitive pricing. Recent regulatory approvals, such as Sanofi's Soliqua‚Ñ¢ and AstraZeneca's Dapagliflozin, highlight ongoing efforts to enhance diabetes management. As the market continues to evolve, players are increasingly targeting emerging economies to expand their market share, addressing the high demand for diabetes treatments in these regions.

Explore More

India Diabetes Care Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Insulins

      1. 2.2.1 Basal or Long Acting Insulins

        1. 2.2.1.1 Lantus (Insulin Glargine)

        2. 2.2.1.2 Levemir (Insulin Detemir)

        3. 2.2.1.3 Toujeo (Insulin Glargine)

        4. 2.2.1.4 Tresiba (Insulin Degludec)

        5. 2.2.1.5 Basaglar (Insulin Glargine)

      2. 2.2.2 Bolus or Fast Acting Insulins

        1. 2.2.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.2.2.2 Humalog (Insulin Lispro)

        3. 2.2.2.3 Apidra (Insulin Glulisine)

      3. 2.2.3 Traditional Human Insulins

        1. 2.2.3.1 Novolin/Actrapid/Insulatard

        2. 2.2.3.2 Humulin

        3. 2.2.3.3 Insuman

      4. 2.2.4 Biosimilar Insulins

        1. 2.2.4.1 Insulin Glargine Biosimilars

        2. 2.2.4.2 Human Insulin Biosimilars

    3. 2.3 Combination drugs

      1. 2.3.1 Insulin combinations

        1. 2.3.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.3.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.3.2 Oral Combinations

        1. 2.3.2.1 Janumet (Sitagliptin and Metformin)

    4. 2.4 Non-Insulin Injectable drugs

      1. 2.4.1 GLP-1 receptor agonists

        1. 2.4.1.1 Victoza (Liraglutide)

        2. 2.4.1.2 Byetta (Exenatide)

        3. 2.4.1.3 Bydureon (Exenatide)

        4. 2.4.1.4 Trulicity (Dulaglutide)

        5. 2.4.1.5 Lyxumia (Lixisenatide)

      2. 2.4.2 Amylin Analogue

        1. 2.4.2.1 Symlin (Pramlintide)

India Diabetes Care Drugs Market Size FAQs

The India Diabetes Care Drugs Market size is expected to reach USD 1.7 billion in 2024 and grow at a CAGR of 3.5% to reach USD 2.01 billion by 2029.

In 2024, the India Diabetes Care Drugs Market size is expected to reach USD 1.7 billion.

India Diabetes Drugs Market Report Snapshots

India Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)